Literature DB >> 17657834

Metastatic colorectal cancer-past, progress and future.

Kathryn Field1, Lara Lipton.   

Abstract

The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common challenge faced by surgeons and physicians. The last decade has seen exciting developments in the management of CRC, with significant improvements in prognosis for patients diagnosed with stage IV disease. Treatment options have expanded from 5-fluorouracil alone to a range of pharmaceutical and interventional therapies, improving survival, and providing a cure in selected cases. Enhanced understanding of the biologic pathways most important in colorectal carcinogenesis has led to a new generation of drugs showing promise in advanced disease. It is hoped that in the near future the treatment paradigm of metastatic CRC will be analogous to that of a chronic illness, rather than a rapidly terminal condition. This overview discusses the epidemiology of advanced CRC and currently available therapeutic options including medical, surgical, ablative and novel modalities in the management of metastatic colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657834      PMCID: PMC4611212          DOI: 10.3748/wjg.v13.i28.3806

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  88 in total

1.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Authors:  F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

Review 2.  The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.

Authors:  D Papamichael
Journal:  Oncologist       Date:  1999

3.  A study of prognostic factors for hepatic resection for colorectal metastases.

Authors:  M Taylor; J Forster; B Langer; B R Taylor; P D Greig; C Mahut
Journal:  Am J Surg       Date:  1997-06       Impact factor: 2.565

4.  Colorectal lung metastases: results of surgical excision.

Authors:  M K McAfee; M S Allen; V F Trastek; D M Ilstrup; C Deschamps; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1992-05       Impact factor: 4.330

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 6.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

7.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

8.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

9.  Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.

Authors:  Z G Zhang; A Harstrick; Y M Rustum
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

10.  Isolated pulmonary recurrence after resection of colorectal hepatic metastases--is resection indicated?

Authors:  Daniel M Labow; Joseph E Buell; Atsushi Yoshida; Seth Rosen; Mitchell C Posner
Journal:  Cancer J       Date:  2002 Jul-Aug       Impact factor: 3.360

View more
  30 in total

Review 1.  Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Authors:  Miguel Jhonatan Sotelo; Beatriz García-Paredes; Carlos Aguado; Javier Sastre; Eduardo Díaz-Rubio
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target.

Authors:  Seyed Khalil Rashidi; Seyed Latif Mousavi Gargari; Walead Ebrahimizadeh
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

3.  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Authors:  Alessandra Silvestri; Valerie Calvert; Claudio Belluco; Michael Lipsky; Ruggero De Maria; Jianghong Deng; Alfonso Colombatti; Francesco De Marchi; Donato Nitti; Enzo Mammano; Lance Liotta; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Clin Exp Metastasis       Date:  2012-09-29       Impact factor: 5.150

4.  Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

Authors:  Alfonso De Stefano; Chiara Carlomagno
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 5.  Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.

Authors:  Woo-Jeong Jeong; Pu-Hyeon Cha; Kang-Yell Choi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.

Authors:  Kimmie Ng; Josep Tabernero; Jimmy Hwang; Emilio Bajetta; Sunil Sharma; Salvatore A Del Prete; Edward R Arrowsmith; David P Ryan; Michaela Sedova; Jin Jin; Kamel Malek; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2013-06-06       Impact factor: 12.531

7.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Accomplishments in 2007 in the management of curable metastatic colorectal cancer.

Authors:  Amit Shah; Steven Alberts; René Adam
Journal:  Gastrointest Cancer Res       Date:  2008-05

Review 9.  Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.

Authors:  Kaitlyn J Kelly; Joyce Wong; Yuman Fong
Journal:  Expert Opin Investig Drugs       Date:  2008-07       Impact factor: 6.206

10.  Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy.

Authors:  Silke Cameron; Diana Hünerbein; Tümen Mansuroglu; Thomas Armbrust; Jens-Gerd Scharf; Harald Schwörer; László Füzesi; Giuliano Ramadori
Journal:  BMC Cancer       Date:  2009-07-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.